Our History
Established in July 2021, Edelen Consulting is a healthcare consulting company located in Indianapolis. Edelen Consulting’s exclusive focus lies within the domain of oncology pricing, access, and reimbursement. We firmly believe that concentrating our efforts solely on these critical areas allows us to provide unparalleled value to our clients.
In today’s dynamic healthcare landscape, key oncology stakeholders continually strive to optimize their approach to treatment pricing, access, and reimbursement.
Edelen Consulting recognizes the paramount importance of these efforts and dedicates its expertise to supporting organizations in achieving their objectives. Our client base includes pharmaceutical and biotech companies, providers, payers, consultants to payers, group purchasing organizations (GPOs), distributors, and professional associations. Leveraging our extensive experience and specialized knowledge, we provide insights and direction that enable organizations to achieve their goals.
BRUCE EDELEN
Ultimately, our mission is to ensure that cancer patients receive optimal access to the treatments they require. By aligning all key stakeholders in the delivery of these treatments, we facilitate the realization of this goal, driving positive outcomes for patients, providers, payers, and industry partners alike.
With over 40 years of invaluable experience in the pharmaceutical industry, Bruce Edelen brings a wealth of expertise. During his distinguished career, Bruce spent 28 years at Eli Lilly and Company, where he honed his skills across various oncology roles, including sales management, sales training, HR, sales operations, pricing, and reimbursement/access. Bruce developed and managed the oncology reimbursement team at Lilly for over 8 years, playing a pivotal role in developing the pricing and contracting strategy for oncology-marketed products, including Gemzar and Alimta. Bruce was also instrumental in the pricing, reimbursement, and access strategies developed for pipeline oncology products.
In 2009, Bruce co-founded Oncology Reimbursement Management (ORM) alongside Ron Schleif, providing invaluable services to numerous pharmaceutical companies until its acquisition by Precision Value and Health in 2022. Serving as Senior Vice President of Precision Value and Health through 2023, Bruce has established himself as a respected figure in the oncology marketplace, renowned for his extensive knowledge and influential relationships in oncology reimbursement.
With a BA in psychology from Miami University, Bruce brings a unique blend of expertise and insights, enriching his ability to deliver exceptional value and strategic guidance to clients in the ever-evolving landscape of oncology pricing, access, and reimbursement.
